US6103258A
(en)
*
|
1996-04-12 |
2000-08-15 |
Simon; David Lew |
Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
|
DE19651551C2
(de)
*
|
1996-12-11 |
2000-02-03 |
Klinge Co Chem Pharm Fab |
Opioidantagonisthaltige galenische Formulierung
|
DE59800046D1
(de)
*
|
1997-02-14 |
1999-12-23 |
Goedecke Ag |
Stabilisierung von naloxonhydrochlorid
|
US20030158220A1
(en)
*
|
1997-11-03 |
2003-08-21 |
Foss Joseph F. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
|
US6559158B1
(en)
*
|
1997-11-03 |
2003-05-06 |
Ur Labs, Inc. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
|
US6274591B1
(en)
|
1997-11-03 |
2001-08-14 |
Joseph F. Foss |
Use of methylnaltrexone and related compounds
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
HU1500214D0
(hu)
|
1997-12-22 |
2002-03-28 |
Euro Celtique Sa |
Opioid agonista és antagonista hatóanyagot tartalmazó gyógyszerkészítmény
|
JP2001526229A
(ja)
|
1997-12-22 |
2001-12-18 |
ユーロ−セルティーク,エス.エイ. |
オピオイド投薬剤形の乱用を防止する方法
|
IT1302682B1
(it)
|
1998-10-16 |
2000-09-29 |
Formenti Farmaceutici Spa |
Composizioni farmaceutiche orali contenenti buprenorfina
|
US20090297602A1
(en)
*
|
1998-11-02 |
2009-12-03 |
Devane John G |
Modified Release Loxoprofen Compositions
|
US6541021B1
(en)
|
1999-03-18 |
2003-04-01 |
Durect Corporation |
Devices and methods for pain management
|
US6835194B2
(en)
*
|
1999-03-18 |
2004-12-28 |
Durect Corporation |
Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
|
MXPA01011480A
(es)
*
|
1999-05-13 |
2002-06-04 |
Unihart Corp |
Composiciones farmaceuticas que comprenden apocodeina y/o sus derivados.
|
AU764453B2
(en)
*
|
1999-10-29 |
2003-08-21 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
OA12215A
(en)
*
|
2000-02-08 |
2006-05-09 |
Euro Celtique Sa |
Tamper-resistant oral opioid agonist formulations.
|
US6716449B2
(en)
|
2000-02-08 |
2004-04-06 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
US7074803B2
(en)
*
|
2001-03-02 |
2006-07-11 |
Durect Corporation |
Opioid formulations
|
CZ20023637A3
(cs)
|
2000-04-07 |
2003-02-12 |
Tap Pharmaceutical Products, Inc. |
Deriváty apomorfinu a způsoby jejich použití
|
WO2001097780A2
(en)
*
|
2000-06-22 |
2001-12-27 |
Pharmasol Ltd |
Pharmaceutical compositions comprising an opioid analgesic
|
CN101317825A
(zh)
|
2000-10-30 |
2008-12-10 |
欧罗赛铁克股份有限公司 |
控释氢可酮制剂
|
US6528521B2
(en)
|
2000-11-15 |
2003-03-04 |
Tap Pharmaceutical Products, Inc. |
Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
|
US20110104214A1
(en)
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
UA81224C2
(uk)
*
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
ES2361148T3
(es)
|
2001-05-11 |
2011-06-14 |
Endo Pharmaceuticals Inc. |
Forma de dosificación de opioides de liberación controlada resistente al abuso.
|
EP1389092B1
(en)
*
|
2001-05-11 |
2006-11-15 |
Endo Pharmaceuticals Inc. |
Abuse-resistant opioid dosage form
|
AU2002339378A1
(en)
*
|
2001-05-22 |
2002-12-03 |
Euro-Celtique |
Compartmentalized dosage form
|
DE60234183D1
(de)
*
|
2001-06-05 |
2009-12-10 |
Univ Chicago |
Verwendung von methylnaltrexon zur behandlung von immunsuppression
|
DE60230632D1
(de)
*
|
2001-07-18 |
2009-02-12 |
Euro Celtique Sa |
Pharmazeutische kombinationen von oxycodon und naloxon
|
US20030044458A1
(en)
*
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
IS7142A
(is)
|
2001-08-06 |
2004-02-05 |
Euroceltique S.A. |
Lyfjasamsetningar, sem innihalda morfíngerandaefni, ásamt losanlegu en hömdu mótlyfi
|
AU2002324624A1
(en)
*
|
2001-08-06 |
2003-02-24 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
EP1429739A1
(en)
|
2001-09-21 |
2004-06-23 |
Egalet A/S |
Polymer release system
|
WO2003024430A1
(en)
|
2001-09-21 |
2003-03-27 |
Egalet A/S |
Morphine polymer release system
|
US20140271788A1
(en)
|
2013-03-15 |
2014-09-18 |
Monosol Rx, Llc |
Sublingual and buccal film compositions
|
DK1436012T3
(en)
*
|
2001-10-18 |
2018-01-22 |
Nektar Therapeutics |
Polymer Conjugates of Opioid Antagonists
|
US20030185882A1
(en)
|
2001-11-06 |
2003-10-02 |
Vergez Juan A. |
Pharmaceutical compositions containing oxybutynin
|
US8329217B2
(en)
*
|
2001-11-06 |
2012-12-11 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Dual controlled release dosage form
|
US20040033253A1
(en)
*
|
2002-02-19 |
2004-02-19 |
Ihor Shevchuk |
Acyl opioid antagonists
|
ATE510534T1
(de)
*
|
2002-03-14 |
2011-06-15 |
Euro Celtique Sa |
Naltrexonhydrochlorid-zusammensetzungen
|
EP2425823A1
(en)
|
2002-04-05 |
2012-03-07 |
Euro-Celtique S.A. |
Pharmaceutical preparation containing oxycodone and naloxone
|
US20050215552A1
(en)
*
|
2002-05-17 |
2005-09-29 |
Gadde Kishore M |
Method for treating obesity
|
JP2005528423A
(ja)
*
|
2002-05-31 |
2005-09-22 |
アルザ・コーポレーシヨン |
オキシコドンの変動性投薬用量の浸透圧的送達のための剤形および組成物
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
AU2003283055A1
(en)
*
|
2002-08-09 |
2004-02-25 |
Grunenthal Gmbh |
Opioid-receptor antagonists in transdermal systems having buprenorphine
|
US20050020613A1
(en)
*
|
2002-09-20 |
2005-01-27 |
Alpharma, Inc. |
Sustained release opioid formulations and method of use
|
EP1551372B8
(en)
*
|
2002-09-20 |
2018-08-01 |
Alpharma Pharmaceuticals LLC |
Sequestering subunit and related compositions and methods
|
DE10250088A1
(de)
*
|
2002-10-25 |
2004-05-06 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
US20050191244A1
(en)
*
|
2002-10-25 |
2005-09-01 |
Gruenenthal Gmbh |
Abuse-resistant pharmaceutical dosage form
|
US20050186139A1
(en)
*
|
2002-10-25 |
2005-08-25 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
DE10250084A1
(de)
*
|
2002-10-25 |
2004-05-06 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
DE10250087A1
(de)
*
|
2002-10-25 |
2004-05-06 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
US20040102476A1
(en)
*
|
2002-11-25 |
2004-05-27 |
Chan Tai Wah |
High concentration formulations of opioids and opioid derivatives
|
US8293799B2
(en)
*
|
2003-12-29 |
2012-10-23 |
Osmotica Keresleedelmo és Szolgáltató KFT |
Osmotic device containing a venlafaxine salt and a salt having an ion in common
|
US20070077301A1
(en)
*
|
2002-12-23 |
2007-04-05 |
Meyer Glenn A |
Venlafaxine osmotic device formulation
|
DE602004031096D1
(de)
|
2003-03-26 |
2011-03-03 |
Egalet As |
Morphin-system mit kontrollierter freisetzung
|
US20040202717A1
(en)
*
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
EP1617846A1
(en)
*
|
2003-04-08 |
2006-01-25 |
Progenics Pharmaceuticals, Inc. |
The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
|
WO2004091665A1
(en)
*
|
2003-04-08 |
2004-10-28 |
Progenics Pharmaceuticals, Inc. |
Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
|
EP2368554B1
(en)
|
2003-04-08 |
2014-12-24 |
Progenics Pharmaceuticals, Inc. |
Pharmaceutical formulations containing methylnaltrexone
|
TWI347201B
(en)
|
2003-04-21 |
2011-08-21 |
Euro Celtique Sa |
Pharmaceutical products,uses thereof and methods for preparing the same
|
EP2316456B1
(en)
|
2003-04-29 |
2017-06-14 |
Orexigen Therapeutics, Inc. |
Compositions for affecting weight loss comprising an opioid antagonist and bupropion
|
US8790689B2
(en)
|
2003-04-30 |
2014-07-29 |
Purdue Pharma L.P. |
Tamper resistant transdermal dosage form
|
MY141815A
(en)
*
|
2003-04-30 |
2010-06-30 |
Purdue Pharma Lp |
Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
DE102005005446A1
(de)
*
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
DE10336400A1
(de)
*
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
US20070048228A1
(en)
*
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
US8075872B2
(en)
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
BRPI0413361B8
(pt)
*
|
2003-08-06 |
2021-05-25 |
Gruenenthal Gmbh |
comprimido seguro contra abuso termo-moldado por extrusão sem descoramento
|
DE102004020220A1
(de)
*
|
2004-04-22 |
2005-11-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
DE102004032051A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
CA2539027C
(en)
*
|
2003-09-25 |
2010-02-23 |
Euro-Celtique S.A. |
Pharmaceutical combinations of hydrocodone and naltrexone
|
MXPA06003450A
(es)
*
|
2003-09-26 |
2006-08-31 |
Johnson & Johnson |
Recubrimiento de farmaco que proporciona alta carga del farmaco y metodos para proporcionar el mismo.
|
CA2540056C
(en)
*
|
2003-09-26 |
2015-03-24 |
Alza Corporation |
Controlled release formulations of opioid and nonopioid analgesics
|
ATE504288T1
(de)
*
|
2003-09-26 |
2011-04-15 |
Alza Corp |
Oros-push-stick für die kontrollierte abgabe von wirkstoffen
|
US20060182692A1
(en)
|
2003-12-16 |
2006-08-17 |
Fishburn C S |
Chemically modified small molecules
|
ES2733764T3
(es)
*
|
2003-12-16 |
2019-12-02 |
Nektar Therapeutics |
Método para la preparación de oligo etilenglicol monodisperso
|
EP1604666A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
LT1765292T
(lt)
|
2004-06-12 |
2018-01-10 |
Collegium Pharmaceutical, Inc. |
Nuo piktnaudžiavimo apsaugotos vaistų formos
|
AR053304A1
(es)
*
|
2004-07-01 |
2007-05-02 |
Gruenenthal Gmbh |
Formas farmaceuticas orales protegidas frente al abuso con liberacion controlada de (1r,2r)-3-(3 dimetilamino-1-etil-2metil-propil)fenol y procedimiento para su produccion.
|
CA2572491A1
(en)
*
|
2004-07-01 |
2006-01-12 |
Gruenenthal Gmbh |
Oral dosage form safeguarded against abuse
|
DE102004032049A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
DE102004032103A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
US8541026B2
(en)
*
|
2004-09-24 |
2013-09-24 |
Abbvie Inc. |
Sustained release formulations of opioid and nonopioid analgesics
|
AR053986A1
(es)
|
2004-12-03 |
2007-05-30 |
Osmotica Pharmaceutical Argent |
Dispositivo osmotico que contiene amantadina y una sal osmotica
|
MX2007008756A
(es)
*
|
2005-01-20 |
2007-09-27 |
Progenics Pharm Inc |
Uso de metilnaltrexona y compuestos relacionados para el tratamiento de disfuncion gastrointestinal postoperatoria.
|
DE102005005449A1
(de)
*
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
EP1702558A1
(en)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
US8524731B2
(en)
*
|
2005-03-07 |
2013-09-03 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
US9662325B2
(en)
|
2005-03-07 |
2017-05-30 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
US9662390B2
(en)
|
2005-03-07 |
2017-05-30 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
US8518962B2
(en)
|
2005-03-07 |
2013-08-27 |
The University Of Chicago |
Use of opioid antagonists
|
AR057035A1
(es)
|
2005-05-25 |
2007-11-14 |
Progenics Pharm Inc |
SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
|
AR057325A1
(es)
|
2005-05-25 |
2007-11-28 |
Progenics Pharm Inc |
Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
|
US20080194611A1
(en)
*
|
2005-06-03 |
2008-08-14 |
Alverdy John C |
Modulation of Cell Barrier Dysfunction
|
EP1951212A2
(en)
*
|
2005-11-22 |
2008-08-06 |
Orexigen Therapeutics, Inc. |
Compositions and methods for increasing insulin sensitivity
|
EP1810678A1
(de)
|
2006-01-19 |
2007-07-25 |
Holger Lars Hermann |
Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution
|
US20100172989A1
(en)
*
|
2006-01-21 |
2010-07-08 |
Abbott Laboratories |
Abuse resistant melt extruded formulation having reduced alcohol interaction
|
US20090022798A1
(en)
*
|
2007-07-20 |
2009-01-22 |
Abbott Gmbh & Co. Kg |
Formulations of nonopioid and confined opioid analgesics
|
US20090317355A1
(en)
*
|
2006-01-21 |
2009-12-24 |
Abbott Gmbh & Co. Kg, |
Abuse resistant melt extruded formulation having reduced alcohol interaction
|
US8916195B2
(en)
*
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
EP2526932B1
(en)
|
2006-06-19 |
2017-06-07 |
Alpharma Pharmaceuticals LLC |
Pharmaceutical composition
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
EP1897543A1
(en)
|
2006-08-30 |
2008-03-12 |
Euro-Celtique S.A. |
Buprenorphine- wafer for drug substitution therapy
|
TW200817048A
(en)
*
|
2006-09-08 |
2008-04-16 |
Wyeth Corp |
Dry powder compound formulations and uses thereof
|
WO2008063301A2
(en)
*
|
2006-10-11 |
2008-05-29 |
Alpharma, Inc. |
Pharmaceutical compositions
|
US20080125592A1
(en)
*
|
2006-10-17 |
2008-05-29 |
Penick Corporation |
Process for preparing oxymorphone, naltrexone, and buprenorphine
|
CA2674915C
(en)
|
2006-10-17 |
2015-06-30 |
Penick Corporation |
Process for preparing oxymorphone
|
TW201811315A
(zh)
|
2006-11-09 |
2018-04-01 |
美商歐瑞根治療有限公司 |
層狀醫藥調配物
|
KR20090090316A
(ko)
|
2006-11-09 |
2009-08-25 |
오렉시젠 세러퓨틱스 인크. |
체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법
|
DE102007011485A1
(de)
*
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
PE20130480A1
(es)
|
2007-03-29 |
2013-05-08 |
Progenics Pharm Inc |
Compuestos heterociclicos como antagonistas del receptor opioide periferico
|
EP3263571B2
(en)
*
|
2007-03-29 |
2023-08-23 |
Progenics Pharmaceuticals, Inc. |
Crystal form of (r)-n-methylnaltrexone bromide and uses thereof
|
MX2009010515A
(es)
|
2007-03-29 |
2009-10-19 |
Wyeth Corp |
Antagonistas del receptor opioide periferico y usos de los mismos.
|
AU2008258596B2
(en)
|
2007-06-04 |
2013-02-14 |
Egalet Ltd |
Controlled release pharmaceutical compositions for prolonged effect
|
PL2197429T3
(pl)
*
|
2007-09-03 |
2016-09-30 |
|
Kompozycje w postaci cząstek do dostarczania słabo rozpuszczalnych leków
|
AU2014250614B2
(en)
*
|
2007-09-04 |
2016-11-10 |
Alpharma Pharmaceuticals, Llc |
A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
|
US20090131466A1
(en)
*
|
2007-09-04 |
2009-05-21 |
Alpharma, Inc. |
Pharmaceutical Compositions
|
AU2008338207A1
(en)
|
2007-12-17 |
2009-06-25 |
Labopharm (Barbados) Limited |
Misuse preventative, controlled release formulation
|
US20100266645A1
(en)
*
|
2007-12-17 |
2010-10-21 |
Alfred Liang |
Pharmaceutical compositions
|
CA2709950A1
(en)
*
|
2007-12-17 |
2009-07-09 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
AU2008338442A1
(en)
*
|
2007-12-17 |
2009-06-25 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
CA2709903A1
(en)
*
|
2007-12-17 |
2009-06-25 |
Alpharma Pharmaceuticals, Llc |
Oral opioid compositions with opioid antagonist
|
AU2015200313B2
(en)
*
|
2007-12-17 |
2016-12-01 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
BRPI0906467C1
(pt)
*
|
2008-01-25 |
2021-05-25 |
Gruenenthal Gmbh |
forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
|
US20090246276A1
(en)
|
2008-01-28 |
2009-10-01 |
Graham Jackson |
Pharmaceutical Compositions
|
US9226907B2
(en)
|
2008-02-01 |
2016-01-05 |
Abbvie Inc. |
Extended release hydrocodone acetaminophen and related methods and uses thereof
|
CA2713568C
(en)
|
2008-02-06 |
2016-09-20 |
Progenics Pharmaceuticals, Inc. |
Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
|
EP2278966B1
(en)
|
2008-03-21 |
2019-10-09 |
The University of Chicago |
Treatment with opioid antagonists and mtor inhibitors
|
MX2010012132A
(es)
*
|
2008-05-05 |
2010-12-06 |
Euro Celtique Sa |
Gel de oxicodona.
|
LT2273983T
(lt)
|
2008-05-09 |
2016-10-25 |
Grünenthal GmbH |
Tarpinės miltelių kompozicijos gamybos būdas ir galutinė kieta dozavimo forma naudojant purškalo kietinimo stadija
|
CA2725930A1
(en)
|
2008-05-30 |
2009-12-30 |
Orexigen Therapeutics, Inc. |
Methods for treating visceral fat conditions
|
US20090311335A1
(en)
*
|
2008-06-12 |
2009-12-17 |
Scott Jenkins |
Combination of a triptan and an nsaid
|
EP2317991B1
(en)
*
|
2008-07-07 |
2017-05-03 |
Euro-Celtique S.A. |
Use of opioid antagonists for treating urinary retention
|
CA2676881C
(en)
|
2008-09-30 |
2017-04-25 |
Wyeth |
Peripheral opioid receptor antagonists and uses thereof
|
PE20190391A1
(es)
|
2008-10-30 |
2019-03-13 |
Gruenenthal Chemie |
Formas de dosificacion del tapentadol novedosas y potentes
|
CA2746888C
(en)
|
2008-12-16 |
2015-05-12 |
Labopharm (Barbados) Limited |
Misuse preventative, controlled release formulation
|
NZ594207A
(en)
|
2009-02-06 |
2013-03-28 |
Egalet Ltd |
Immediate release composition resistant to abuse by intake of alcohol
|
MX347106B
(es)
|
2009-03-10 |
2017-04-12 |
Euro-Celtique S A * |
Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
|
RU2589823C2
(ru)
*
|
2009-04-09 |
2016-07-10 |
Алкермес Фарма Айэленд Лимитед |
Композиция для доставки лекарственных средств
|
AU2010265213B2
(en)
|
2009-06-24 |
2012-08-23 |
Egalet Ltd. |
Controlled release formulations
|
EP2456427B1
(en)
|
2009-07-22 |
2015-03-04 |
Grünenthal GmbH |
Hot-melt extruded controlled release dosage form
|
AU2010275754B2
(en)
|
2009-07-22 |
2014-05-15 |
Grünenthal GmbH |
Tamper-resistant dosage form for oxidation-sensitive opioids
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
ES2762113T3
(es)
|
2010-01-11 |
2020-05-22 |
Nalpropion Pharmaceuticals Inc |
Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
|
WO2011095314A2
(en)
*
|
2010-02-03 |
2011-08-11 |
Grünenthal GmbH |
Preparation of a powdery pharmaceutical composition by means of an extruder
|
IT1398930B1
(it)
*
|
2010-03-24 |
2013-03-28 |
Molteni & C |
Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi.
|
US20120015031A1
(en)
|
2010-07-14 |
2012-01-19 |
Grunenthal Gmbh |
Novel gastro-retentive dosage forms
|
WO2012028319A1
(en)
|
2010-09-02 |
2012-03-08 |
Grünenthal GmbH |
Tamper resistant dosage form comprising inorganic salt
|
MX2013002293A
(es)
|
2010-09-02 |
2013-05-09 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a alteracion que comprende un polimero anionico.
|
ES2444591T3
(es)
|
2010-10-28 |
2014-02-25 |
Acino Pharma Ag |
Medicamento con el principio activo hidromorfona con estabilidad al almacenamiento mejorada
|
WO2012075337A2
(en)
|
2010-12-01 |
2012-06-07 |
Spinal Modulation, Inc. |
Directed delivery of agents to neural anatomy
|
WO2012085656A2
(en)
|
2010-12-22 |
2012-06-28 |
Purdue Pharma L.P. |
Encased tamper resistant controlled release dosage forms
|
KR20140075807A
(ko)
|
2010-12-23 |
2014-06-19 |
퍼듀 퍼머 엘피 |
탬퍼 저항성 고체 경구 투여 형태
|
BR112014002022A2
(pt)
|
2011-07-29 |
2017-02-21 |
Gruenenthal Gmbh |
comprimido resistente à violação proporcionando liberação de fármaco imediata
|
LT2736497T
(lt)
|
2011-07-29 |
2017-11-10 |
Grünenthal GmbH |
Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu
|
HRP20211539T1
(hr)
|
2011-09-19 |
2021-12-24 |
Orexo Ab |
Sublingvalne tablete otporne na zloupotrebu koje sadrže buprenorfin i nalokson
|
EA201400590A1
(ru)
|
2011-11-17 |
2014-11-28 |
Грюненталь Гмбх |
Устойчивая к разрушению пероральная фармацевтическая лекарственная форма, содержащая фармакологически активный ингредиент, опиоидный антагонист и/или средство, вызывающее отвращение, полиалкиленоксид и анионный полимер
|
EP2782558A4
(en)
*
|
2011-11-22 |
2015-03-18 |
Watson Pharmaceuticals Inc |
MISSABLE TABLET WITH IMMEDIATE RELEASE
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
US20130225697A1
(en)
|
2012-02-28 |
2013-08-29 |
Grunenthal Gmbh |
Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
|
AU2013248351B2
(en)
|
2012-04-18 |
2018-04-26 |
Grunenthal Gmbh |
Tamper resistant and dose-dumping resistant pharmaceutical dosage form
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
EP4104824A1
(en)
|
2012-06-06 |
2022-12-21 |
Nalpropion Pharmaceuticals LLC |
Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
|
NZ704011A
(en)
|
2012-07-06 |
2016-04-29 |
Egalet Ltd |
Abuse deterrent pharmaceutical compositions for controlled release
|
MX2015010041A
(es)
|
2013-02-05 |
2015-10-30 |
Purdue Pharma Lp |
Formulacion farmaceuticas resistentes a la alteracion.
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
US9517208B2
(en)
|
2013-03-15 |
2016-12-13 |
Purdue Pharma L.P. |
Abuse-deterrent dosage forms
|
CA2907950A1
(en)
|
2013-05-29 |
2014-12-04 |
Grunenthal Gmbh |
Tamper-resistant dosage form containing one or more particles
|
JP6466417B2
(ja)
|
2013-05-29 |
2019-02-06 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
二峰性放出プロファイルを有する改変防止(tamper−resistant)剤形
|
CN105431144A
(zh)
|
2013-06-05 |
2016-03-23 |
思康脑侒股份有限公司 |
阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
|
EA032465B1
(ru)
|
2013-07-12 |
2019-05-31 |
Грюненталь Гмбх |
Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления
|
CN105517551A
(zh)
|
2013-07-23 |
2016-04-20 |
欧洲凯尔特公司 |
用于在患有疼痛和导致肠生态失调和/或提高肠细菌移位风险之疾病的患者中治疗疼痛的羟考酮与纳洛酮的组合
|
WO2015023675A2
(en)
|
2013-08-12 |
2015-02-19 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded immediate release abuse deterrent pill
|
AU2014356581C1
(en)
|
2013-11-26 |
2020-05-28 |
Grunenthal Gmbh |
Preparation of a powdery pharmaceutical composition by means of cryo-milling
|
WO2015095391A1
(en)
|
2013-12-17 |
2015-06-25 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
US9492444B2
(en)
|
2013-12-17 |
2016-11-15 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
CN106572980A
(zh)
|
2014-05-12 |
2017-04-19 |
格吕伦塔尔有限公司 |
包含他喷他多的防篡改即释胶囊制剂
|
CN106456550A
(zh)
|
2014-05-26 |
2017-02-22 |
格吕伦塔尔有限公司 |
避免乙醇剂量倾泻的多颗粒
|
US9707184B2
(en)
|
2014-07-17 |
2017-07-18 |
Pharmaceutical Manufacturing Research Services, Inc. |
Immediate release abuse deterrent liquid fill dosage form
|
US9132096B1
(en)
|
2014-09-12 |
2015-09-15 |
Alkermes Pharma Ireland Limited |
Abuse resistant pharmaceutical compositions
|
CA2964628A1
(en)
|
2014-10-20 |
2016-04-28 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extended release abuse deterrent liquid fill dosage form
|
AU2016251854A1
(en)
|
2015-04-24 |
2017-10-19 |
Grunenthal Gmbh |
Tamper-resistant dosage form with immediate release and resistance against solvent extraction
|
JP2018526414A
(ja)
|
2015-09-10 |
2018-09-13 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
|
US20170312226A1
(en)
*
|
2016-04-28 |
2017-11-02 |
Ascent Pharmaceuticals, Inc. |
Pharmaceutical dosage forms
|
WO2017222575A1
(en)
|
2016-06-23 |
2017-12-28 |
Collegium Pharmaceutical, Inc. |
Process of making more stable abuse-deterrent oral formulations
|